METROPOLISBSEMetropolis Healthcare LtdHighPositive
Announced Wed, 13 May · 20:04 IST

Press Release

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF

METROPOLIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-5.0%1-day move
₹550.00
prior close
₹600.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-4.3-4.8-5.2-6.2-5.0-7.9-7.7-5.5-4.5-4.3-3.5-4.4+1.3
Up moveDown movePending
AI summary

Metropolis Healthcare reported robust Q4FY26 results with revenue of INR 425 Cr, up 23% YoY. EBITDA jumped 71% to INR 108 Cr with margin expanding to 25.4% from 18.5% a year ago. PAT rose 75% to INR 51 Cr, reflecting strong operational efficiency and cost controls. The company crossed the 5,000+ centres milestone and saw patient volumes grow 11% YoY and test volumes increase 14% YoY. B2C revenues grew 20% YoY while B2B revenues increased 28% YoY, driven by rising preventive healthcare adoption and stronger doctor relationships. The Board also approved a dividend of ₹1 per share.

Likely market impact

The strong margin expansion and double-digit revenue growth indicate improving operational leverage and market share gains. The dividend declaration provides additional shareholder returns. These results suggest healthy underlying demand for diagnostics services and efficient cost management.